Citi Initiates Alnylam (ALNY) With Buy Rating

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 12 Best Revenue Growth Stocks to Buy According to Wall Street Analysts. On May 19, Citi initiated coverage of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), giving the stock a Buy rating and setting the price target at $380.

The research firm noted that the expanded launch of Amvuttra for ATTR-CM has “no doubt been impressive.” Citi also highlighted that the year-to-date pullback has created “an attractive long-term entry point.” According to the firm, concerns about competition have pressured the stock, but it sees “more tailwinds than headwinds for Amvuttra.”

Earlier, on May 12, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shared new results from the HELIOS-B Phase 3 study of vutrisiran in patients with ATTR-CM. The company said the new findings add to a growing body of evidence supporting vutrisiran and show the durability of transthyretin (TTR) knockdown along with a well-characterized safety profile.

The data showed consistent clinical benefits across patient groups, including patients with a high disease burden. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) said these results support the use of vutrisiran as a first-line treatment option for the rapidly progressive and life-threatening condition.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a global biopharmaceutical company that is widely known as the leader in RNA interference (RNAi) therapeutics. It focuses on developing transformative therapies with the potential to prevent, halt, or reverse rare and prevalent diseases.

READ NEXT: 10 AI Stocks That Are About to Explode and 10 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts.

Disclosure: None.  Follow Insider Monkey on Google News.